Clik here to view.
UW, Microsoft Research Aim to Turn Northwest Into a Neural Engineering Hotspot
Luke Timmerman The minute I walked into an auditorium at Microsoft Research in Redmond last night, I knew this was going to be a fun event. In foot-high letters, someone wrote on a white board, “FOOD...
View ArticleClik here to view.
Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To...
Luke Timmerman Celgene and a San Francisco-based cancer drug startup called Quanticel Pharmaceuticals have struck an unusual agreement in which the big company is getting the inside track on a new...
View ArticleClik here to view.
SD Life Sciences Roundup: Arena, PatientSafe, MEI Pharma, & More
Bruce V. Bigelow Here’s my roundup of new developments from San Diego’s life sciences cluster over the past week. —After initially rejecting a new drug application from San Diego’s Arena...
View ArticleClik here to view.
Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker
Luke Timmerman Celgene became one of the world’s biggest biotech companies because of its drug for blood cancers that scientists say works at least partly by stimulating an immune reaction against...
View ArticleClik here to view.
Presage Snags $13M from Celgene to Pick Winning Cancer Drug Combos
Luke Timmerman Seattle-based Presage Biosciences has found another big partner that thinks it can help separate the winners from the losers in early cancer drug development, before the really big...
View ArticleClik here to view.
From Assets to Zen: Building Successful Drug Hunting Relationships
John Mendlein [Editor's Note: This post was co-authored by Jessica Yingling, founder of Little Dog Communications.] A wise person once said, “Select your partner wisely. Because that person will be...
View ArticleClik here to view.
Forma Strikes $200M Deal With Celgene to Discover Cancer Drugs
Luke Timmerman Forma Therapeutics has never had trouble finding partners who want access to its early-stage drug discovery team, when most companies are cutting back there. But the Watertown, MA-based...
View ArticleClik here to view.
Trusting Your Partners: A Chat With Celgene’s George Golumbeski
Ben Fidler It’s no secret that biotech IPOs, for the first time in at least 10 years, are suddenly white hot. Companies with sparse evidence from clinical trials, or those with drugs that have failed...
View ArticleClik here to view.
San Diego’s PharmAkea Raises Capital, Forms Alliance with Celgene
Bruce V. Bigelow San Diego-based PharmAkea Therapeutics, founded last year by key scientists from Amira Pharmaceuticals, said it has raised $10 million in Series A funding from San Francisco’s Bay...
View ArticleClik here to view.
Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs
Ben Fidler OncoMed Pharmaceuticals (NASDAQ: OMED) may be a long ways away from actually winning FDA approval of a product, but it just got a big vote of confidence from Celgene that it’s on the right...
View ArticleClik here to view.
Seattle Jobs? Big Biotech Gives And Takes Away (Mostly The Latter)
Alex Lash Reporting a 25 percent jump in profits, Amgen (NASDAQ: AMGN) also dealt a blow to Seattle’s biotech job market today. The Thousand Oaks, CA-based biotech drug maker announced a huge round of...
View ArticleClik here to view.
Arch, Flagship to Anchor NYCEDC’s $150M NY Biotech Fund
Ben Fidler [Updated, 3/31/15, 3:35pm ET] New York biotech entrepreneurs have been asking the same question for years: How can Manhattan ever truly foster life sciences startups and build a biotech...
View ArticleClik here to view.
East Coast Biotech Roundup: Celldex, Ensemble, CRISPR Battle & More
Biotech indices had rallied over the past week, but that’s before the drug pricing issue returned to the spotlight in Washington. The Centers for Medicare & Medicaid Services, as the New York...
View ArticleClik here to view.
Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs
For close to a decade, Tom Daniel and George Golumbeski comprised perhaps one of the best-known dealmaking duos in biopharma, striking a slew of alliances that established Summit, NJ-based Celgene as...
View ArticleClik here to view.
BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders
For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today...
View ArticleClik here to view.
Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo
If you’re among those frustrated by the lack of talk about health and science in the three presidential debates, this week perhaps brought you a wee consolation prize. The steady drip of hacked...
View ArticleClik here to view.
Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing
A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known...
View ArticleClik here to view.
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins
Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life...
View ArticleClik here to view.
ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest
ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge of its most substantial clinical test to date, the company has also...
View ArticleClik here to view.
Vividion Lands $101M from Celgene to Develop Protein-Targeting Drugs
Vividion Therapeutics is partnering with Celgene to develop new drugs that modulate protein levels as a way of treating disease.Celgene (NASDAQ: CELG) will pay San Diego-based Vividion $101 million up...
View Article
